A multi-centred, randomized, double blinded and placebo controlled treatment effectiveness Phase III clinical trial for early stage Parkinson's disease patients
Phase of Trial: Phase III
Latest Information Update: 20 Jun 2018
Price : $35 *
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 20 Jun 2018 Status changed from planning to recruiting, according to a Luye Pharma Group media release.
- 06 Jun 2018 According to a Luye Pharma media release, the company expects to begin the trial this year.
- 16 Apr 2018 New trial record